Venom immunotherapy in patients with allergic reactions to insect stings

被引:9
|
作者
Incorvaia, Cristoforo [1 ]
Mauro, Marina [2 ]
Gritti, Bruna L. [1 ]
Makri, Eleni [1 ]
Ridolo, Erminia [3 ]
机构
[1] ASST Pini CTO, Cardiac Pulm Rehabil, Via Bignami 1, Milan, Italy
[2] Univ Parma, Dept Clin & Expt Med, Parma, Italy
[3] St Anna Hosp, ASST Lariana, Allergy Unit, Como, Italy
关键词
Hymenoptera venom allergy; venom immunotherapy; efficacy; safety; duration of treatment; mastocytosis; CONVERTING ENZYME-INHIBITORS; HYMENOPTERA VENOM; BEE VENOM; SYSTEMIC MASTOCYTOSIS; FATAL ANAPHYLAXIS; ADVERSE-REACTIONS; DOUBLE POSITIVITY; MAJOR ALLERGENS; ACE-INHIBITORS; BETA-BLOCKERS;
D O I
10.1080/1744666X.2018.1413350
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Allergy to Hymenoptera (Apis mellifera, Vespula species, Polistes species, Vespa crabro) venom can be safely and effectively treated by venom immunotherapy (VIT), which in the 40 years since its introduction has been able to prevent reactions to stings, and to treatment as well, though systemic reactions, occasionally severe, are possible. Areas covered: We reviewed the recent literature on VIT by searching in PubMed for the terms 'venom immunotherapy' and 'Hymenoptera venom immunotherapy' to highlight the current status of VIT and the likely development in the coming years. Expert commentary: VIT, provided the correct choice of the venom and adequate venom preparations and maintenance doses are used, is a treatment of great value in preventing systemic reactions to Hymenoptera stings. A 5-year duration ensures a prolonged tolerance to stings following VIT discontinuation, unless patients suffer from mastocytosis. In fact, due to reports of fatal reactions after stopping VIT, patients with mastocytosis, or with very severe reactions to stings, need an indefinite duration of treatment.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 50 条
  • [21] Quality of life in patients allergic to Hymenoptera venom who refuse specific immunotherapy
    Mikulski, Damian
    Smorawska-Sabanty, Ewa
    Kowalski, Marek L.
    ALERGIA ASTMA IMMUNOLOGIA, 2016, 21 (02): : 133 - 137
  • [22] Immunotherapy for Hymenoptera venom allergy compared with real-life stings: Are we doing our best?
    Pecoraro, Luca
    Giovannini, Mattia
    Mori, Francesca
    Saretta, Francesca
    Barni, Simona
    Castagnoli, Riccardo
    Arasi, Stefania
    Mastrorilli, Carla
    Liotti, Lucia
    Caminiti, Lucia
    Novembre, Elio
    CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (02) : 209 - 211
  • [23] Long-term protection after stopping venom immunotherapy:: Results of re-stings in 200 patients
    Lerch, E
    Müller, UR
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (05) : 606 - 612
  • [24] Safety Profile of Hymenoptera Venom Immunotherapy (VIT) in Monosensitized Patients: Lack of New Sensitization to Nontreated Insect Venom
    Spoerl, D.
    Bircher, A. J.
    Scherer, K.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2011, 21 (01) : 22 - 27
  • [25] Difficult immunotherapy in a mastocytosis patient allergic to wasp venom
    Drouet, M.
    Lavigne, C.
    REVUE FRANCAISE D ALLERGOLOGIE, 2017, 57 (08): : 590 - 592
  • [26] Potentials for improvement of the efficacy of venom immunotherapy - what is possible?
    Rueff, F.
    Przybilla, B.
    ALLERGOLOGIE, 2014, 37 (09) : 368 - 373
  • [27] Venom immunotherapy protocols in the pediatric population: how to choose?
    Saretta, Francesca
    Giovannini, Mattia
    Pessina, Benedetta
    Barni, Simona
    Liccioli, Giulia
    Sarti, Lucrezia
    Tomei, Leonardo
    Fazi, Camilla
    Pegoraro, Francesco
    Valleriani, Claudia
    Ricci, Silvia
    Azzari, Chiara
    Novembre, Elio
    Mori, Francesca
    FRONTIERS IN PEDIATRICS, 2023, 11
  • [28] Component-Resolved Evaluation of the Risk and Success of Immunotherapy in Bee Venom Allergic Patients
    Rosiek-Biegus, Marta
    Pawlowicz, Robert
    Kopec, Agnieszka
    Kosinska, Magdalena
    Wrzesniak, Marta
    Nittner-Marszalska, Marita
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (06)
  • [29] Venom immunotherapy: adverse reactions and treatment failure
    Rueff, Franziska
    Przybilla, Bernhard
    CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 4 (04) : 307 - 311
  • [30] WHAT ARE THE FACTORS AFFECTING THE HYPERSENSITIVITY REACTIONS DURING VENOM IMMUNOTHERAPY AND RE-STING REACTIONS? TERTIARY REFERENCE CENTER EXPERIENCE
    Dalgic, Ceyda Tunakan
    Camyar, Asuman
    Dilek, Emel
    Bulut, Gokten
    Demir, Meryem
    Gulbahar, Okan
    Gokmen, Emine Nihal Mete
    Kokuludag, Ali
    Sin, Aytul Zerrin
    NOBEL MEDICUS, 2023, 19 (03): : 193 - 199